Project responsibilities

Similar documents
National Blueprint System Slovakia Kick-Off Meeting

National Blueprint System Slovakia Kick-Off Meeting

MAHs and CMOs considerations and objectives to meet upcoming regulations in 2019

Belgian Medicines Verification Organisation. End User Implementation

FIMVO END USER AND ISV WORKSHOP. Paul Mills - EMVO

FMD Implementation Status Report

Verification processes in the supply chain. Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO

FMD Implementation Status Report

The Blueprint approach

National Medicine Verification System

What To Do or Not To Do? Utility of Medication Traceability to the Patient

Guideline for EMVO and NMVO stakeholders: recommendations for alert handling and prevention process. January 2019

Falsified Medicines Directive: Overview from the Irish Medicines Verification Organisation (IMVO) LEONIE CLARKE - 28 TH MARCH HUG

The European Stakeholder Model A Medicines Verification System for Europe (ESM)

Update Version 1.0 Based on the information available at that date of NCA.

Inside EU FMD and the Delegated Acts A Compliance Primer

Top 15 Questions and Answers. EU FMD Safety Features and Verification

Background to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016

Falsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017

European Medicines Verification Organisation: Requirements for the European Medicines Verification System URS Lite

EMVO FMD Workshop Brussels 13. December 2016

Project Status. Tero Vesa Technical project manager, FiMVO

The Falsified Medicines Directive. What pharmacy teams need to do

EU Falsified Medicines Directive. Gareth Jones

NMVO on-boarding presentation

FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE

Digital Medicines. FMD in England - Challenges and opportunities in pharmacy

Welcome! 9.30 Medicines Verification System general update Maija Gohlke-Kokkonen, General Manager, FiMVO - Contracting & fees

The Journey

EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update

HI, emvo. Author's Signature. Approver's Signature. ROnoMnP TO NMVO AND NMVS IUPITUENTATION. Interim General Manager. Interim Quality Assurance

FMD edusammud ja väljakutsed. Mai 26, 2017 Tartu. Ravimiameti infopäev. Mart Levo REKS Eesti.

IT Provider Workshop for the EMVS NBS

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

The Danish Generic Medicines Industry Association (IGL)

Experience with Serialization Implementation as one powerful measure to protect our patients. Françoise Hirth

GS1 Ireland Healthcare User Group (HUG) Information Day

Safety Features Required by the Falsified Medicines Directive 2011/62/EU

Falsified Medicines Directive Procedure for managing Alerts generated by the verification system

EMVO ON-BOARDING HOW TO CONNECT TO THE EU HUB? VERSION OCTOBER 2017

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager

Serialisation. GS1 Standards in Healthcare. Standards Certification Education & Training Publishing Conferences & Exhibits

The role of the European Commission during the FMD implementation phase Agnès Mathieu DG SANTE European Commission

STATUS REPORT Status of the project to implement the Falsified Medicines Directive

Implementation of the safety features in medicinal products for human use

DEVELOPING APPLICATIONS USING MICROSERVICES AND MICROSOFT AZURE SERVICE FABRIC 1

ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma

The way forward for FMD in community pharmacy

Implementation of the safety features in medicinal products for human use

Practical implementation of the Falsified Medicines Directive

GS1 Ireland Healthcare User Group (HUG) Information Day

Verification of Pharmaceutical Products at the Point of Dispense. An EFPIA update

Safety features for medicinal products for human use. Questions & Answers. 1. Document history

Falsified Medicines Directive Procedure for managing Alerts generated by the verification system

IMPLEMENTAÇÃO DA DIRETIVA DOS MEDICAMENTOS FALSIFICADOS E ATOS DELEGADOS. Pedro Ferreira ANF

Jerome Lepeintre. Delegation of the European Union to China and Mongolia

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD)

STATUS REPORT Status of the project to implement the Falsified Medicines Directive

European Union (EU) Falsified Medicines Directive

Global Serialisation Developments and the Need for Convergence. Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015

Safety features for medicinal products for human use

Timeline for the Drug Supply Chain and Security Act

The new European Regulations the Importance of GS1 standards in the Healthcare sector

Being Prepared for Track and Trace: DSCSA 101

Implementation Reality - Traceability

The German securpharm Initiative. Christian Riediger, Bayer Pharma AG

Mass Serialization and Traceability Implementation in the Pharma Industry. Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland

Implementation of EU Falsified Medicines Directive

Case Study: how reports of falsified medicinal products can impact wholesale distributors

Counterfeit Drugs and Supply Chain Security

Implementation Reality Traceability

The value partnership between NHS, industry and other providers

A closer look at the EU- FMD Safety Features Delegated Act: 10 things pharma manufacturers need to consider

Federal agency for medicines and health products. Seminar LM4: Falsified Medicines Directive - Did they forget the hospital pharmacy?

Health systems and products Medical products quality, safety and innovation VERSION 8

A FREQUENTZ WHITE PAPER: Meeting Traceability Regulations In The World s Two Largest Pharmaceutical Markets Frequentz. All rights reserved.

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY 26 FEBRUARY 2016

Serialisation End User View

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Taking a Leap Toward Global Supply Chain Efficiency - Part II

Pharmaceutical Serialization in Brasil. 12 Mar 2015

Drug Supply Chain Security Act Implementation Track and Trace Issues in 2017

Process and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager

Healthcare logistics. Business Solution. Individual logistic solutions out of one hand

Primary Distribution Activities

Verification of Pharmaceutical Products at the Point of Dispense. Status of the EFPIA Project

BUILDING FOR EU FMD: 5 SERIALISATION LEADERS SHARE HOW TO PREPARE WHAT TO EXPECT IN GERMANY, ITALY, SPAIN, AND SCANDINAVIA

Regulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues

Pro Generika e.v., German Association of Generic Manufacturers, Comments on. European Commission s. Concept Paper on

Healthcare. Frequently Asked Questions (FAQs) by the Pharmaceutical Industry in Preparing for the U.S. DSCSA

Agenda. The Past: 1990 s. Healthcare. Supply Efficiencies Pallet Through Retail Packages The Present:

Discussion paper on recent developments of the Russian system of goods labelling with identification means

Real life expertise from Arvato Systems + Systec & Services

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Europe Fights Back against Counterfeit Medication with the European Falsified Medicines Directive (2011/62/CE)

BSWH Technician Continuing Education 2016 Part 2: Pharmacy Law - Controlled Substance Security & Drug Supply Chain Security Act (DSCSA) Contact

EXISTING TECHNOLOGIES AND TRACK AND TRACE MODELS IN USE AND TO BE DEVELOPED BY MEMBER STATES. TABLE: EXPERIENCES IN COUNTRIES (updated November 2017)

Manufacturers serialisation challenges with FMD & DR implementation

Scan4Safety. Implications on Hospital Pharmacy and effect on delivery of healthcare November 2017

Shortages of medicinal products due to manufacturing and quality problems

Transcription:

Project responsibilities Tallinn November 24th, 2017

Our Mission Falsified / counterfeit medicines are a serious risk for the citizens all around the world New legislation published on the 9th February 2016 as delegated act This new legislation is mandatory for all EU members Pan-European strategy to fight illegal medicine products Based on a Point-of-Dispense Verification Manufacturer MAH Wholesaler Pharmacy Patient

Where the data goes MAH EU Hub Parallel Distributor NMVS NMVS and many more countries! Wholesaler Pharmacy Wholesaler Pharmacy

Challenges Many stakeholders are involved Organisators REKS EMVO Software providers Solidsoft (EMVS/EU Hub) Arvato Pharmacy/hospital/wholesaler SW providers/it departments Authorities Primary distributors Marketing authorization holders Contract manufacturers Wholesalers Parallel distributors Public pharmacies Hospital pharmacies Secondary distributors Army Prisons Airlines Nursing homes Drug treatment centers NGOs...

Master the Challenges Organize Cooperation The stakeholders must learn to act together in a new context. New overarching processes must be established. Stakeholders are depending on each other, i.e. delays and errors will propagate and accumulate downstream. => Let s have a (very) short look at which dependencies exist.

We have to master one central challenge (2) Organize Cooperation The stakeholders must learn to act together in a new context. New overarching processes must be established. Stakeholders are depending on each other, i.e. delays and errors will propagate and accumulate downstream. => Let s have a (very) short look at which dependencies exist.

A complex web of stakeholders must learn to cooperate smoothly Exploitants CMOs Authorities Authorities approve new serialized medicaments EMVO, EU Hub MAHs use the EU Hub to upload their product/pack data Arvato uses the EU Hub to download product/pack data; Arvato implements changes of the URS Authorities Authorities define their needs concerning the data to provided NMVO Legend Stakeholder A Stakeholder B Stakeholder B depends on stakeholder A The CMOs have to prepare their production for serialization. Exploitants MAHs Exploitants Wholesalers receive medicaments from the MAHs MAHs use the NMVS (data analysis) Wholesalers use the NMVS Arvato Parallel distributors use the NMVS REKS defines specific requirements (e.g. needs of the authorities) Software suppliers depend on Arvato to adapt/connect their software products Wholesalers Parallel distributors receive medicaments from the wholesalers Parallel Distributors Pharmacies use the NMVS Software Suppliers Pharmacies receive medicaments from the MAHs Pharmacies receive medicaments from the wholesalers Pharmacies Officines, hôpitaux Par. distributors use the EU Hub EMVO, EU Hub Pharmacies use the software products of the software suppliers

What exactly needs to be done? (1) All MAHs must Introduce serialization for their products (package design, regulatory approval, production preparation, production start) Synchronize with their manufacturers (CMOs) Synchronize with their wholesalers Connect with the EU-Hub and start uploading product data and pack data Adapt their IT systems to handle serialized products (incl. EU Hub interface) Manage falsifications including false positives All wholesalers/par. distributors must Synchronize with their MAHs Adapt their IT systems to handle serialized products (incl. NMVS interface) Manage both serialized and non-serialized products for a transition time Wait for serialized products to be delivered by their MAHs Manage falsifications including false positives

What exactly needs to be done? (2) All pharmacies must Align with their software suppliers Introduce upgraded IT systems for scanning of serialized products Onboard to the NMVS system (certificates, access rights, etc.) Train their employees Adapt their daily business processes Wait for serialized packs to propagate through the supply chain Manage detected falsifications including false positives All software suppliers must Understand the NMVS web service interface and specify the required changes to their software products Plan and reserve implementation capacities/efforts Implement and test the specified changes to their software products Coordinate the rollout of their new software product releases to the pharmacies

What exactly needs to be done? (3) The EU Hub will for the first time have to...... handle transactions from multiple countries... handle multi-market products/transactions... handle inter-market transactions REKS will have to...... keep an overview of all the stakeholders involved and their respective progress in the project... align with the Estonian authorities... manage detected falsifications including false positives General aspects Further URS changes by EMVO are likely to occur in the future and will have to be considered

Conclusions Numerous interwoven processes cause a high global complexity. The ecosystem as a whole needs sufficient time to settle down. There is no time to waste until go live. All stakeholders need to be aware of that.

Thank you